Fort Lee, NJ, (February 27, 2018): PixarBio Corporation, developers of NeuroReleaseTM NR14, a 14-day post-surgical pain treatment, clarifies its position on NR14 treating “Trigeminal Neuralgia” and post-surgical pain.
Just Part of Frank's Story
PixarBio Clinical Advisory Board member, Dr. Anita Gupta, on CNN with Michaela Pereira discussing Tiger Woods and Opioids
For more than two decades, drugmakers, doctors and patients have been looking for a better pain medication than opioids, which have ravaged families and local communities with their addictive powers. It’s a wide open field and a multi-billion dollar market opportunity, yet startlingly little progress has been made.
Cambridge, Massachusetts (March 30, 2017): PixarBio Corporation (OTC: PXRB) developers of NeuroReleaseTM, announced Founder and CEO Frank Reynolds will be discussing NeuroRelease, PixarBio’s answer to the opiate war at the 2017 MassBio Annual Meeting as a member of the Panel on Pain & Addiction at the Royal Sonesta Boston, Longfellow Room, in Cambridge, MA, at 8:30am on March 31, 2017.
Cambridge, Massachusetts (February 13, 2017): PixarBio Corporation (OTC: PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in late 2018 for our 14-day post-surgical pain treatment, announced today that it will be attending the BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City, NY, from February 13 – 14, 2017.
Cambridge, Massachusetts (January 27, 2017): PixarBio Corporation (formerly traded on OTCQX as PXRB) announced today that, pursuant to a January 23, 2017 Order, trading of its securities were temporarily suspended by the Securities and Exchange Commission. The suspension is scheduled to last from January 23, 2017 through February 3, 2017 at 11:59 PM. PixarBio is …